Combination strategies are rapidly redefining treatment for HER2-positive solid tumors. In this video interview, Robert Iannone, executive vice president, global head of R&D and chief medical officer at Jazz Pharmaceuticals, discusses the evolution of HER2-targeted treatment approaches across multiple tumor types.
Iannone explains how tumor heterogeneity, immune activation and resistance mechanisms are pushing the field toward multimodal regimens. He also highlights emerging HER2 technologies, including bispecific and biparatopic antibodies, and explains how their innovative mechanisms are designed to target HER2 biology in differentiated ways.
From gastroesophageal and biliary tract cancers to other HER2-expressing solid tumors, this discussion offers insight into how biology-driven combination strategies are reshaping HER2 treatment and influencing future development.